Federal Register Notice: FDA has determined the regulatory review period for Novartis’ Exjade (deferasirox) is 2,288 days for extension of a patent that claims the human drug product. Exjade is indicated for treating chronic iron overload due to blood transfusions in patients two years of age and older. To view this notice, click here.
